9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV

Expert Review of Vaccines

Volumn 14, Issue 11, 2015, Pages 1405-1419

  Pitisuttithum, Punnee ^a   Velicer, Christine ^b   Luxembourg, Alain ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cancer prevention; genital warts; human papillomavirus; pre cancers; prophylactic vaccine

Indexed keywords

WART VIRUS VACCINE;

AGE DISTRIBUTION; ANUS CANCER; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CLINICAL PROTOCOL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEALTH ECONOMICS; HUMAN; IMMUNOGENICITY; MEDICAL RESEARCH; NONHUMAN; OROPHARYNX CANCER; PENIS CANCER; PRECANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VAGINA CANCER; VULVA CANCER; WART VIRUS; CARCINOMA; COMPLICATION; CONDYLOMATA ACUMINATA; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; IMMUNOLOGY; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; VIROLOGY;

CARCINOMA; CONDYLOMATA ACUMINATA; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; HUMANS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS;

EID: 84945449576     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1089174     Document Type: Article

References (88)

1. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (Suppl 5): F55-70
2. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10 (4): 321-2
3. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl 5): F12-23
4. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 (Suppl 3): S11-25
5. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl 5): F123-38
6. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88 (1): 63-73
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356 (19): 1928-43
8. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 (19): 1915-27
9. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369 (9580): 2161-70
10. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007; 369: 1693-702
11. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364 (5): 401-11
12. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365 (17): 1576-85
13. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012; 30 (Suppl 5): F139-48
14. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015; 16 (5): e206-16
15. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208 (3): 385-93
16. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32 (1): 26-32
17. Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013; 40 (1): 28-31
18. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206 (11): 1645-51
19. Delere Y, Remschmidt C, Leuschner J, et al. Human papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014; 14 (1): 87
20. Brotherton J, Fridman M, Saville M, Gertig D. First indication of a possible impact on cervical abnormalities following a national HPV vaccination program in Victoria, Australia. 2010. Available from: http://hpv2010.org/mwg-internal/de5fs23hu73ds/progress?id=RKGuErfdN1. [Last accessed 13 June 2011]
21. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377 (9783): 2085-92
22. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31 (1): 109-13
23. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11: 227
24. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106 (3): djt460
25. Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther 2014; 36 (1): 17-23
26. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348: g1458
27. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346: f2032
28. Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013; 13: 140
29. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87 (7): 544-7
30. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102 (5): 833-5
31. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013; 20 (2): 17-20
32. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206 (6): 860-6
33. Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40 (2): 130-5
34. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57 (7): 929-34
35. Mariani L, Vici P, Suligoi B, et al. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015. [. Epub ahead of print]
36. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906
37. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2009; 29: 95-101
38. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302 (7): 750-7
39. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine 2011; 29 (46): 8279-84
40. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012; 271 (2): 193-203
41. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166 (12): 1140-8
42. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275 (4): 398-408
43. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf 2013; 36 (6): 393-412
44. Scheller NM, Svanstrom H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313 (1): 54-61
45. Brown MJ, Seitz H, Towne V, et al. Development of neutralizing monoclonal antibodies for oncogenic HPV types. Clinical Vaccines and Immunology 2014; 21 (4): 587-93
46. de Villiers E-M, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27
47. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12 (10): 781-9
48. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14 (10): 958-66
49. Muñoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85
50. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014; 23 (10): 1997-2008
51. Castellsague X, Saah A, Luxembourg A, Velicer C. Potential Impact Of A Nine-Valent Vaccine On Human Papillomavirus (HPV) Related Cervical Disease In Women Aged 16-45 Years Of Age, By Region. European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2015. Available from: www.eurogin.com/2015/. [Last accessed 20 May 2015]
52. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7 (1): 38
53. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11): 1048-56
54. de Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49 (16): 3450-61
55. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136 (1): 98-107
56. Alemany L, Saunier M, Tinoco L, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples. Eur J Cancer 2014; 50 (16): 2846-54
57. Van Damme P, Leroux-Roels G, Simon P, et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. Vaccine 2014; 32 (29): 3694-705
58. Luxembourg A, Brown D, Bouchard C, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother 2015; 11 (6): 1313-22
59. Caulfield MJ, Shi L, Wang S, et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin 2007; 3 (4): 139-45
60. Ruiz W, McClements WL, Jansen KU, Esser MT. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 2005; 3 (1): 2
61. Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001). Available from: https://clinicaltrials.gov/ct2/show/NCT00543543
62. Chen J, Gesser R, Luxembourg A. A seamless Phase IIB/III adaptive outcome trial: design rationale and implementation challenges. Clin Trials 2015; 12 (1): 84-90
63. Joura EA, Giuliano AR, Iversen OE, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med 2015; 372 (8): 711-23
64. Luxembourg A, Bautista O, Moeller E, et al. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials 2015; 42: 18-25
65. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10 (1): 108-15
66. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12 (8): 959-69
67. Roberts C, Hess E, Matys K, et al. Development of a human papillomavirus competitive Luminex immunoassay for nine HPV types. Hum Vaccin Immunother 2015; 10 (8): 2168-74
68. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2: 868-78
69. A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002). Available from: https://clinicaltrials.gov/ct2/show/NCT00943722
70. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet 2006; 368 (9548): 1706-28
71. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118 (5): 2135-45
72. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40 (6): 564-71
73. World Health Organization Expert Committe on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/human-papillomavirus/HPVg%20Final%20BS%202050%20 pdf. [Last accessed 20 May 2015, 2006]
74. Van Damme P, Olsson S-E, Block S. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics 2015; 136 (1): e28-39
75. Multivalent HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year Old Men and Women (V503-003). Available from: https://clinicaltrials.gov/ct2/show/NCT01651949
76. Castellsague X, Giuliano A, Goldstone S, et al. Tolerability and immunogenicity of a multivalent HPV L1 virus-like particle vaccine in 16-to 26-year-old men. EUROGIN 2015, February 4-7. Available from: www.eurogin.com/2015/images/pdf/eurogin-2015-abstracts-part-2.pdf. [Last accessed 18 May 2015]
77. Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012; 19 (2): 261-7
78. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015; 64 (11): 300-4
79. Sadler L, Saftlas A, Wang W, et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004; 291 (17): 2100-6
80. Chao A, Lin CT, Hsueh S, et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol 2004; 190 (4): 1046-51
81. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004; 191 (1): 114-20
82. Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother 2014; 10 (7): 2106-8
83. Schuchat A. HPV "coverage". N Engl J Med 2015; 372 (8): 775-6
84. Meeting of the Strategic Advisory Group of Experts (SAGE) on immunization, April 2014-conclusions and recommendations. Wkly Epidemiol Rec 2014; 89: 221-36
85. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014. 89: 465-92. Available from: www.who.int/wer. [Last accessed 21 May 2015]
86. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199 (6): 805-14
87. Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001). Available from: https://clinicaltrials.gov/ct2/show/NCT00260039
88. A study to evaluate tolerability and immunogenicity of V504 administered concomitantly with GARDASIL (V504-001)(COMPLETED). Available from: https://clinicaltrials.gov/ct2/show/NCT00551187